Although there is a great body of pre-clinical evidence that RANK signaling promotes proliferation and (bone) metastatic progression of breast cancer [23, 28, 29], it still controversially discussed, whether targeted inhibition of RANK signalling by denosumab treatment will confer clinical benefit in patients with early breast cancer. The gene discussed is TNFRSF11A; the disease is breast carcinoma.